Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Closure

This article was originally published in The Tan Sheet

Executive Summary

Manufacturer of Johnson & Johnson/Ethicon's Liquid Band-Aid expects to launch line extension treating finger cracks before the end of 2003, company states. Closure also plans to launch one other product in the line in 2003, CEO Daniel Pelak says during 2004 guidance call Nov. 20. The extension likely will treat acne or itching (1"The Tan Sheet" Oct. 6, 2003, In Brief). Regarding a third product that the firm had planned on shipping before year-end, Pelak reports its launch timetable "has been slowed [until next spring] due to additional questions" by FDA. Liquid Band-Aid products will become available in 15 European countries in 2004. Closure expects Liquid Band-Aid products to comprise 20% of its 2004 revenues, which are projected to rise 34% from 2003 revenues to between $45 mil. and $47 mil. Liquid Band-Aid products made up roughly 15% of 2003 revenues. Net income next year is expected to be $9.7 mil. to $10.5 mil., the firm says...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel